Erasca, Inc. (ERAS)
14.02
+0.66
(+4.90%)
USD |
NASDAQ |
Jun 11, 16:00
14.02
0.00 (0.00%)
After-Hours: 19:00
Erasca Debt to Equity Ratio : 0.1168 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.1168 |
| December 31, 2025 | 0.145 |
| September 30, 2025 | 0.1388 |
| June 30, 2025 | 0.1328 |
| March 31, 2025 | 0.1272 |
| December 31, 2024 | 0.1225 |
| September 30, 2024 | 0.1176 |
| June 30, 2024 | 0.1196 |
| March 31, 2024 | 0.2144 |
| December 31, 2023 | 0.1764 |
| September 30, 2023 | 0.1674 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.1589 |
| March 31, 2023 | 0.1502 |
| December 31, 2022 | 0.1338 |
| September 30, 2022 | 0.1491 |
| June 30, 2022 | 0.07 |
| March 31, 2022 | 0.0693 |
| December 31, 2021 | 0.0412 |
| September 30, 2021 | 0.0419 |
| June 30, 2021 | 0.0134 |
| March 31, 2021 | 0.0131 |
| December 31, 2020 | 0.0278 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Revolution Medicines, Inc. | 0.2915 |
| Tango Therapeutics, Inc. | 0.0837 |
| Kymera Therapeutics, Inc. | 0.0523 |
| Bridgebio Oncology Therapeutics, Inc. | 0.0071 |
| ImmunityBio, Inc. | -1.293 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 461.23M |
| Total Liabilities (Quarterly) | 67.71M |
| Shareholders Equity (Quarterly) | 393.53M |
| Current Ratio | 9.518 |
| Net Debt Paydown Yield | 0.02% |